Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
3.300
+0.120 (3.77%)
Apr 29, 2026, 3:04 PM CST
SHE:002390 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 1,114 | 1,016 | 805.98 | 899.18 | 624.65 |
Cash & Short-Term Investments | 1,114 | 1,016 | 805.98 | 899.18 | 624.65 |
Cash Growth | 9.69% | 26.00% | -10.37% | 43.95% | -64.84% |
Accounts Receivable | 2,468 | 2,691 | 3,036 | 3,091 | 3,082 |
Other Receivables | 256 | 320.24 | 324.63 | 448.8 | 600.56 |
Receivables | 2,724 | 3,012 | 3,361 | 3,540 | 3,682 |
Inventory | 901.23 | 1,060 | 1,001 | 1,033 | 935.71 |
Prepaid Expenses | - | 0.02 | 0.03 | 0.02 | 0.02 |
Other Current Assets | 103.97 | 164.39 | 243.61 | 334.34 | 333.72 |
Total Current Assets | 4,843 | 5,252 | 5,412 | 5,806 | 5,576 |
Property, Plant & Equipment | 2,339 | 2,426 | 2,518 | 2,672 | 2,706 |
Long-Term Investments | 402.52 | 337.47 | 340.47 | 343.84 | 347.41 |
Goodwill | 593.64 | 603.75 | 603.75 | 607.35 | 607.35 |
Other Intangible Assets | 176.61 | 189.54 | 180.18 | 204.37 | 217.65 |
Long-Term Deferred Tax Assets | 110.27 | 81.87 | 74.14 | 62.81 | 55.61 |
Long-Term Deferred Charges | 58.11 | 69.3 | 81.84 | 97.21 | 118.36 |
Other Long-Term Assets | 67 | 68.57 | 35 | - | - |
Total Assets | 8,591 | 9,028 | 9,245 | 9,794 | 9,629 |
Accounts Payable | 822.55 | 927.97 | 903.15 | 977.24 | 993.43 |
Accrued Expenses | 22.39 | 37.15 | 35.27 | 32.99 | 40.93 |
Short-Term Debt | 269.61 | 603.54 | 809.86 | 1,368 | 1,390 |
Current Portion of Long-Term Debt | 106.12 | - | - | - | - |
Current Portion of Leases | - | 3 | 4.4 | 2.51 | - |
Current Income Taxes Payable | 30.16 | 7.6 | 21.09 | 17.21 | 17.79 |
Current Unearned Revenue | 25.77 | 25.94 | 27.98 | 33.24 | 55.44 |
Other Current Liabilities | 187.37 | 201.68 | 256.82 | 255.56 | 256.6 |
Total Current Liabilities | 1,464 | 1,807 | 2,059 | 2,687 | 2,755 |
Long-Term Debt | 37 | 160 | - | - | - |
Long-Term Leases | 18.03 | 21 | 21.12 | 22.02 | 24.81 |
Long-Term Unearned Revenue | 20.22 | 19.52 | 22.04 | 18.89 | 20.38 |
Long-Term Deferred Tax Liabilities | 13.19 | 0.73 | 0.84 | 0.56 | - |
Other Long-Term Liabilities | 0.28 | 0.29 | 0.31 | 0.32 | 0.34 |
Total Liabilities | 1,553 | 2,008 | 2,103 | 2,729 | 2,800 |
Common Stock | 1,944 | 1,944 | 1,944 | 1,944 | 2,027 |
Additional Paid-In Capital | 4,403 | 4,403 | 4,403 | 4,402 | 4,693 |
Retained Earnings | 569.93 | 563.43 | 633.34 | 462.74 | 354.99 |
Treasury Stock | -199.93 | -199.93 | -127.49 | - | -455.38 |
Comprehensive Income & Other | 72.93 | - | - | - | - |
Total Common Equity | 6,790 | 6,710 | 6,852 | 6,808 | 6,620 |
Minority Interest | 247.95 | 309.87 | 289.69 | 256.55 | 208.74 |
Shareholders' Equity | 7,038 | 7,020 | 7,142 | 7,065 | 6,829 |
Total Liabilities & Equity | 8,591 | 9,028 | 9,245 | 9,794 | 9,629 |
Total Debt | 430.76 | 787.55 | 835.38 | 1,393 | 1,415 |
Net Cash (Debt) | 683.13 | 227.97 | -29.4 | -493.42 | -790.6 |
Net Cash Growth | 199.66% | - | - | - | - |
Net Cash Per Share | 0.36 | 0.11 | -0.02 | -0.26 | -0.43 |
Filing Date Shares Outstanding | 1,898 | 1,896 | 1,907 | 1,944 | 1,944 |
Total Common Shares Outstanding | 1,898 | 1,896 | 1,907 | 1,944 | 1,944 |
Working Capital | 3,379 | 3,445 | 3,353 | 3,119 | 2,822 |
Book Value Per Share | 3.58 | 3.54 | 3.59 | 3.50 | 3.41 |
Tangible Book Value | 6,020 | 5,917 | 6,068 | 5,997 | 5,795 |
Tangible Book Value Per Share | 3.17 | 3.12 | 3.18 | 3.08 | 2.98 |
Buildings | - | 2,517 | 2,516 | 2,578 | 2,396 |
Machinery | - | 1,716 | 1,722 | 1,697 | 1,641 |
Construction In Progress | - | 145.02 | 58.06 | 24.98 | 92.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.